FTSE 100 today: closes higher as UK inflation surprises; GBP lower, Ithaca report
Cathie Wood’s ARK ETFs have made notable moves in the market on Friday, April 25, 2025, with a mix of both buying and selling across various sectors. The most significant trade of the day was the sale of 66,135 shares of Veracyte Inc (NASDAQ:VCYT), amounting to a substantial $2,125,578. This move comes as part of a recent trend, with ARK also reducing its position in Veracyte Inc in the previous sessions.
On the buying side, ARK’s ARKK ETF invested heavily in the biotech sector by purchasing 65,958 shares of Intellia Therapeutics Inc (NASDAQ:NTLA), with a total dollar value of $539,536. This acquisition indicates a growing interest in the gene-editing company, as ARK has been accumulating shares over the past week.
Another significant buy was Symbotic Inc (NASDAQ:SYM), where ARK’s ARKQ ETF added 8,140 shares worth $179,568. This automation technology company seems to be gaining ARK’s confidence, as this follows a smaller purchase earlier in the week.
In the technology sector, ARK’s ARKQ ETF bought 925 shares of Baidu Inc (NASDAQ:BIDU), totaling $82,787. Baidu, known as China’s Google (NASDAQ:GOOGL), has been another stock that ARK has been gradually adding to its portfolio.
However, not all trades were bullish. ARK’s ARKK ETF sold 1,255 shares of Meta Platforms Inc (NASDAQ:META), with a total dollar value of $669,103. This sale is a part of a continued reduction in the social media giant, which has been a trend for ARK in recent days.
Additionally, ARK’s ARKW ETF sold 984 shares of UiPath Inc (NYSE:PATH) for $11,138, further scaling down its investment in the automation software company, consistent with previous days’ activities.
Investors closely follow Cathie Wood’s ARK ETFs for their forward-looking investment strategies, particularly in disruptive technologies. Today’s trades underscore ARK’s dynamic approach to portfolio management, continuously adjusting positions to align with their vision of future market trends.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.